Program
senaparib
Also written as “IMP4297”, “IMP4297(20mg)” and “IMP4297(10mg)”.
Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Small Cell Lung Carcinoma, led by Impact Therapeutics.
Furthest: phase 2, since Sep 3, 201912 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Impact Therapeutics | 120 open or running | phase 2since Sep 3, 2019 | Jan 8, 2018 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2018First studies: 2 phase 1 studies in Breast NeoplasmsFirst studyNCT03508011, NCT03507543
- Jul 29, 2019Phase 1 study in Solid TumorNCT04057729 · 16 enrolled · China
- Sep 3, 2019Phase 2 study in Ovarian NeoplasmsNCT04089189 · 93 enrolled · China
- Apr 15, 2020Phase 1 study in Solid TumorNCT04351165 · 18 enrolled · Australia
- Jun 14, 2020Phase 2 study in Small Cell Lung CarcinomaNCT04434482 · 59 enrolled · United States, Australia, China and more
- Sep 29, 2020Phase 1 study in Solid TumorNCT04584515 · 32 enrolled · China
- Oct 12, 2021Phase 1 study in Solid TumorNCT05109832 · 6 enrolled · China
- May 20, 20222 phase 1 studies in Solid TumorNCT05391048, NCT05390944
- May 23, 2025Phase 1 study in Solid TumorNCT07019194 · 40 enrolled · China
- Jun 12, 2025Phase 1 study in Solid TumorNCT07030439 · 32 enrolled · China
TargetBeta
“Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07030439Solid Tumor · China | 1 | Completed | Oct 12, 2021 | 32 |
| NCT07019194Solid Tumor · China | 1 | Completed | Jul 15, 2024 | 40 |
| NCT05391048Solid Tumor · China | 1 | Completed | Jul 21, 2022 | 36 |
| NCT05390944Solid Tumor · China | 1 | Completed | Aug 1, 2022 | 28 |
| NCT05109832Solid Tumor · China | 1 | Completed | Dec 6, 2021 | 6 |
| NCT04584515Solid Tumor · China | 1 | Completed | Mar 8, 2021 | 32 |
| NCT04434482Small Cell Lung Carcinoma · United States, Australia, China and more | 2 | Completed | Apr 29, 2024 | 59 |
| NCT04351165Solid Tumor · Australia | 1 | Completed | Feb 11, 2021 | 18 |
| NCT04089189Ovarian Neoplasms · China | 2 | Completed | Jun 30, 2023 | 93 |
| NCT04057729Solid Tumor · China | 1 | Completed | Sep 27, 2019 | 16 |
| NCT03508011Breast Neoplasms · China | 1 | Completed | Dec 16, 2020 | 57 |
| NCT03507543Breast Neoplasms · Australia | 1 | Completed | Sep 24, 2020 | 39 |
How it is read
Names in the registry
- “IMP4297”, 5 entries
- “IMP4297(20mg)”, 2 entries
- “IMP4297(10mg)”, 2 entries
- “14C-IMP4297”, 1 entry
- “Senaparib 10 mg strength capsules manufactured by WuXi STA (Wuxi) Co., Ltd.”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
- Ovarian Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.